An International Randomised Clinical Trial of Therapeutic Interventions to Assess the Effects on Outcome in Adults With Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation.
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 333
- 试验地点
- 14
- 主要终点
- Overall survival (all randomisations)
研究概览
简要总结
Treatment options for older adults with Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS) are limited. Although stem cell transplantation remains one of the most effective treatments it is associated with severe side effects which have until recently prevented its use in older adults. In the last decade the use of reduced intensity transplants has allowed the extension of the potentially curative effect of transplantation to older patients in whom it was previously precluded. Although a major advance such transplants are associated with a high risk of disease relapse particularly in patients with high risk disease.
This study will evaluate new transplant strategies with the aim of improving the outcome of patients with AML and high risk MDS after stem cell transplantation. Three approaches to improve transplant outcome will be studied:
- Comparing the new pre-transplant consolidation therapy vyxeos with the standard consolidation therapy (Randomisation 1 is now closed to recruitment).
- Comparing new conditioning therapies in patients under the age of 55 years
- Comparing new conditioning therapies in patients aged 55 and over
All patients will be followed up for a minimum of 2 years.
详细描述
This is a randomised, international, phase II/III, multicentre, clinical trial in patients with AML and MDS undergoing allo-SCT. Patients with AML or MDS who fulfil the eligibility criteria will be invited to participate in the trial across centers performing allo-SCT.
Patients will be randomised to treatment based on a minimisation algorithm prepared at the Cancer Research UK Clinical Trials Unit (CRCTU).
Randomisation 1 (R1) (closed to recruitment) will compare the novel consolidation therapy vyxeos with the standard consolidation therapy intermediate dose cytarabine.
Randomisation 2 (R2) will compare the novel conditioning regimen thiotepa/busulphan/fludarabine (TBF) with the standard conditioning therapy fludarabine/busulphan (FB4) in patients aged under 55 years of age.
Randomisation 3 (R3) will compare the novel conditioning regimen mini thiotepa/busulphan/fludarabine (mini TBF) with the standard regimen fludarabine/busulphan (FB2) in patients aged 55 years of age and over (or patients aged under 55 with comorbidities).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligibility Criteria for Randomisation 1 (closed to recruitment) Inclusion Criteria for Randomisation 1
- •Patients (≥ 18 years old) with a morphological documented diagnosis of AML or MDS who are deemed fit for allo-SCT with one of the following disease characteristics:
- •Patients in 1st complete remission (CR1) defined as < 5% blasts
- •Patients in 2nd complete remission (CR2) defined as < 5% blasts
- •Secondary AML (defined as previous history of MDS, antecedent haematological disease or chemotherapy exposure) in CR1 or 2 defined as < 5% blasts MDS
- •Patients with advanced or high risk MDS with an IPSS-R of ≥3.5 (intermediate 3.5 or higher) including intermediate or high risk CMML (e.g. CPSS int-2 or high risk)
- •Patients with an identified HLA identical sibling or suitable matched unrelated donor (suitable match defined as no greater than a single allele mismatch at HLA-A, -B, -C, DQB1 or DRβ1)
- •Patients must be considered suitable/fit to undergo allo-SCT as clinically judged by the Local Investigator
- •Females of and male patients of reproductive potential (i.e., not post-menopausal or surgically sterilised) must use appropriate, highly effective, contraception from the point of commencing therapy until 6 months after treatment
- •Patients have given written informed consent
- •Patients willing and able to comply with scheduled study visits and laboratory tests
排除标准
- •for Randomisation 1
- •Patients with contraindications to receiving allo-SCT
- •Female patients who are pregnant or breastfeeding. All women of childbearing potential must have a negative pregnancy test before commencing treatment
- •Adults of reproductive potential not willing to use appropriate, highly effective, contraception during the specified period
- •Patients with renal or hepatic impairment as clinically judged by the Local Investigator
- •Patients with active infection, HIV-positive or chronic active HBV or HCV.
- •Patients with a prior malignancy, except lobular breast carcinoma in situ, fully resected basal cell or squamous cell carcinoma of skin or treated cervical carcinoma in situ, incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis (TNM) clinical staging system), previous MDS, CMML, MPN resulting in secondary AML. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously will not be allowed.
- •History of serious hypersensitivity reaction to cytarabine, daunorubicin, or any component of the Vyxeos formulation.
- •Known history of Wilson's disease or other copper-related metabolic disorder since copper gluconate is a component of the Vyxeos formulation
- •Eligibility Criteria for Randomisation 2 Inclusion Criteria for Randomisation 2
- •Patients aged between 18 - 54 years with a morphological documented diagnosis of AML or MDS who are deemed fit for a MAC allo-SCT with one of the following disease characteristics: AML o Patients in 1st complete remission (CR1) defined as < 5% blasts
- •Patients in 2nd complete remission (CR2) defined as < 5% blasts
- •Secondary AML (defined as previous history of MDS, antecedent haematological disease or chemotherapy exposure) in CR1 or 2 defined as < 5% blasts
- •Must have received at least two courses of prior intensive chemotherapy prior to transplant unless there are exceptional circumstances. Patients with AML who have achieved CR with Venetoclax based induction regimen treatment as only prior treatment, will also be eligible.
- •o Patients with advanced or high risk MDS (with an IPSS-R of ≥3.5 (intermediate 3.5 or higher) including intermediate or high risk CMML (e.g. CPSS int-2 or high risk), who have < 10% blasts at the time of randomisation following intensive chemotherapy (including R1 randomisation) or hypomethylating agents if necessary
- •Patients with an identified HLA identical sibling or suitable matched unrelated donor (suitable match defined as no greater than a single allele mismatch at HLA-A, -B, -C, DQB1 or DRβ1)
- •Patients with an ECOG performance status of 0, 1 or 2
- •Patients considered suitable/fit to undergo a MAC allo-SCT as clinically judged by the Local Investigator including:
- •Adequate hepatic and renal function as determined by full blood count and biochemistry assessment
- •Resolution of any toxic effects of prior therapy (including radiotherapy, chemotherapy or surgical procedures)
- •Performance of cardiac or pulmonary function tests (where there is a previous history of cardiac or pulmonary impairment)
- •Females of and male patients of reproductive potential (i.e., not post-menopausal or surgically sterilised) must use appropriate, highly effective, contraception from the point of commencing therapy until 12 months after treatment
- •Patients have given written informed consent
- •Patients willing and able to comply with scheduled study visits and laboratory tests Exclusion Criteria for Randomisation 2
- •1. Patients with contraindications to receiving a MAC allo-SCT
- •Female patients who are pregnant or breastfeeding. All women of childbearing potential must have a negative pregnancy test before commencing treatment
- •Adults of reproductive potential not willing to use appropriate, effective, contraception during the specified period
- •Patients with renal or hepatic impairment as clinically judged by the Local Investigator
- •Patients with active infection, HIV-positive or chronic active HBV or HCV
- •Patients with a prior malignancy, except lobular breast carcinoma in situ, fully resected basal cell or squamous cell carcinoma of skin or treated cervical carcinoma in situ, incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis (TNM) clinical staging system), previous MDS, CMML, MPN resulting in secondary AML. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously will not be allowed.
- •Eligibility Criteria for Randomisation 3 Inclusion Criteria for Randomisation 3
- •Patients aged between 55 years or older with a morphological documented diagnosis of AML or MDS who are deemed fit for a RIC allo-SCT (or under the age of 55 with comorbidities which are deemed by the local investigator to preclude safe delivery of a MAC allo-SCT may be considered per investigators discretion) with one of the following disease characteristics: AML
- •Patients in 1st complete remission (CR1) defined as < 5% blasts
- •Patients in 2nd complete remission (CR2) defined as < 5% blasts
- •Secondary AML (defined as previous history of MDS, antecedent haematological disease or chemotherapy exposure) in CR1 or 2 defined as < 5% blasts
- •Must have received at least two courses of prior intensive chemotherapy prior to transplant unless there are exceptional circumstances. Patients with AML who have achieved CR with Venetoclax based induction regimen treatment, as only prior treatment, will also be eligible.
- •Patients with advanced or high risk MDS (with an IPSS-R of ≥3.5 (intermediate 3.5 or higher) including intermediate or high risk CMML (e.g. CPSS int-2 or high rsk), who have < 10% blasts at the time of randomisation following intensive chemotherapy (including R1 randomisation) or hypomethylating agents if necessary
- •Patients with an identified HLA identical sibling or suitable matched unrelated donor (suitable match defined as no greater than a single allele mismatch at HLA-A, -B, -C, DQB1 or DRβ1)
- •Patients with an ECOG performance status of 0, 1 or 2
- •Patients considered suitable/fit to undergo a RIC allo-SCT as clinically judged by the Local Investigator including: a. Adequate hepatic and renal function as determined by full blood count and biochemistry assessment b. Resolution of any toxic effects of prior therapy (including radiotherapy, chemotherapy or surgical procedures) c. Performance of cardiac or pulmonary function tests (where there is a previous history of cardiac or pulmonary impairment
- •Females of and male patients of reproductive potential (i.e., not post-menopausal or surgically sterilised) must use appropriate, highly effective, contraception from the point of commencing therapy until 12 months after treatment
- •Patients have given written informed consent
- •Patients willing and able to comply with scheduled study visits and laboratory tests Exclusion Criteria for Randomisation 3
- •Patients with contraindications to receiving a RIC allo-SCT
- •Female patients who are pregnant or breastfeeding. All women of childbearing potential must have a negative pregnancy test before commencing treatment
- •Adults of reproductive potential not willing to use appropriate, effective, contraception during the specified period
- •Patients with renal or hepatic impairment as clinically judged by the Local Investigator
- •Patients with active infection, HIV-positive or chronic active HBV or HCV
- •Patients with a prior malignancies, except lobular breast carcinoma in situ, fully resected basal cell or squamous cell carcinoma of skin or treated cervical carcinoma in situ, incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis (TNM) clinical staging system), previous MDS, CMML, MPN resulting in secondary AML. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously will not be allowed.
研究组 & 干预措施
R1: Vyxeos
First Randomisation (closed to recruitment) - experimental arm: Vyxeos (29mg/65mg/m^2 administered by intravenous infusion over 90 minutes on days 1 and 3)
干预措施: Vyxeos (Drug)
R1: Intermediate dose Cytarabine
First Randomisation (closed to recruitment) - control arm: Intermediate dose Cytarabine (1g/m^2 administered by intravenous infusion over 2 hours on days 1-5 inclusive)
干预措施: Cytarabine (Drug)
R2: FB4
Second Randomisation - under 55 years - control arm: Fludarabine (40mg/m^2 days -7, -6, -5, and -4), Busulphan (3.2mg/kg days -7, -6, -5 and -4)
干预措施: Fludarabine (Drug)
R2: FB4
Second Randomisation - under 55 years - control arm: Fludarabine (40mg/m^2 days -7, -6, -5, and -4), Busulphan (3.2mg/kg days -7, -6, -5 and -4)
干预措施: Busulphan (Drug)
R2: TBF
Second Randomisation - under 55 years - experimental arm: Thiotepa (5mg/kg day -7 and -6), Busulphan (3.2mg/kg days -5, -4 and -3), Fludarabine (50mg/m^2 days -5, -4 and -3)
干预措施: Fludarabine (Drug)
R2: TBF
Second Randomisation - under 55 years - experimental arm: Thiotepa (5mg/kg day -7 and -6), Busulphan (3.2mg/kg days -5, -4 and -3), Fludarabine (50mg/m^2 days -5, -4 and -3)
干预措施: Thiotepa (Drug)
R3: FB2
Third Randomisation - 55 years and over (or under 55 with comorbidities) - control arm: Fludarabine (30mg/m^2 days -6, -5, -4, -3 and -2), Busulphan (3.2mg/kg days -6 and -5)
干预措施: Fludarabine (Drug)
R2: TBF
Second Randomisation - under 55 years - experimental arm: Thiotepa (5mg/kg day -7 and -6), Busulphan (3.2mg/kg days -5, -4 and -3), Fludarabine (50mg/m^2 days -5, -4 and -3)
干预措施: Busulphan (Drug)
R3: FB2
Third Randomisation - 55 years and over (or under 55 with comorbidities) - control arm: Fludarabine (30mg/m^2 days -6, -5, -4, -3 and -2), Busulphan (3.2mg/kg days -6 and -5)
干预措施: Busulphan (Drug)
Mini-TBF
Third Randomisation - 55 years and over (or under 55 with comorbidities) - experimental arm: Thiotepa (5mg/kg day -6), Busulphan (3.2mg/kg days -5 and -4), Fludarabine (50mg/m^2 days -5, -4, and -3)
干预措施: Fludarabine (Drug)
Mini-TBF
Third Randomisation - 55 years and over (or under 55 with comorbidities) - experimental arm: Thiotepa (5mg/kg day -6), Busulphan (3.2mg/kg days -5 and -4), Fludarabine (50mg/m^2 days -5, -4, and -3)
干预措施: Busulphan (Drug)
Mini-TBF
Third Randomisation - 55 years and over (or under 55 with comorbidities) - experimental arm: Thiotepa (5mg/kg day -6), Busulphan (3.2mg/kg days -5 and -4), Fludarabine (50mg/m^2 days -5, -4, and -3)
干预措施: Thiotepa (Drug)
结局指标
主要结局
Overall survival (all randomisations)
时间窗: 12 and 24 months
Defined as time from entering the relevant randomisation to the relevant question until death from any cause. Patients who are alive at the end of the trial or have been lost to follow up will be censored at their date last seen. For randomisations 2 and 3 this outcome will also be calculated as time from transplantation in order to run a sensitivity analysis.
次要结局
- Disease-free survival(From date of randomisation through to study completion, an average of 6 years)
- Incidence of primary graft failure - R2 and R3 only(From date of randomisation through to study completion, an average of 6 years)
- Cumulative incidence of disease relapse(From date of randomisation through to study completion, an average of 6 years)
- Quality of Life measured by EQ-5D questionnaires, recorded at multiple timepoints - R2 and R3 only(Assessed at pre transplant, day 28 and months 3, 6, 9, 12, 18 and 24)
- Change in MRD status - R1 only(Assessed at baseline and pre-transplant)
- Non-relapse mortality(From date of randomisation through to study completion, an average of 6 years)
- Incidence of acute and chronic Graft versus Host Disease - R2 and R3 only(From date of randomisation through to study completion, an average of 6 years)
- Incidence of toxicities reported as per CTCAE V4.0(From start of treatment until 28 days after last dose of treatment)
- Quality of Life measured by EORTC-QLQ-C30 questionnaires, recorded at multiple timepoints - R2 and R3 only(Assessed at pre transplant, day 28 and months 3, 6, 9, 12, 18 and 24)